Biliary cancers, chemotherapy, and cetuximab

David Malka; Valérie Boige; Michel Ducreux

doi:10.1016/S1470-2045(10)70267-9

Biliary cancers, chemotherapy, and cetuximab

David Malka, Valérie Boige, Michel Ducreux

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	1110-1112
Nombre de pages	3
journal	The Lancet Oncology
Volume	11
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/S1470-2045(10)70267-9
état	Publié - 1 déc. 2010

Accès au document

10.1016/S1470-2045(10)70267-9

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{2b31855beede4f7b80fa9f55367d3e31,

title = "Biliary cancers, chemotherapy, and cetuximab",

author = "David Malka and Val{\'e}rie Boige and Michel Ducreux",

note = "Funding Information: The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.",

year = "2010",

month = dec,

day = "1",

doi = "10.1016/S1470-2045(10)70267-9",

language = "English",

volume = "11",

pages = "1110--1112",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "12",

}

TY - JOUR

T1 - Biliary cancers, chemotherapy, and cetuximab

AU - Malka, David

AU - Boige, Valérie

AU - Ducreux, Michel

N1 - Funding Information: The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.

PY - 2010/12/1

Y1 - 2010/12/1

UR - http://www.scopus.com/inward/record.url?scp=78649600834&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(10)70267-9

DO - 10.1016/S1470-2045(10)70267-9

M3 - Comment/debate

C2 - 21126684

AN - SCOPUS:78649600834

SN - 1470-2045

VL - 11

SP - 1110

EP - 1112

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -